Integrated RSS Management Solution Simplifies Information Management and Delivery

The Thomson CorporationThomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, announced the launch of Enterprise Alert Manager, an integrated RSS management and collaboration solution designed to simplify information distribution across an organization by allowing for easy deployment while reducing email load and network strain. It also helps centralize content management, including managing users' credentials for password protected content.

With Enterprise Alert Manager, information managers can access, manage and deliver information from any RSS-based source, including Dialog, the Internet and internal, proprietary content. Enterprise Alert Manager also provides the ability to enhance content with editorial reviews, tag records with separate categories, customize information feeds for specific constituencies and provide users access to RSS content feeds via email, web browsers, portals, intranets, desktop applications and mobile devices.

"As more organizations begin to see the value of Web 2.0 technologies and services, such as RSS, blogs, wikis and folksonomies, we are committed to providing our customers with the ability to leverage Web 2.0 enabled content whether it comes from Thomson Scientific, our customers or the Open Web," said Eddie Watkins, director of product management, Corporate Markets group, Thomson Scientific. "The combination of Thomson Scientific's breadth and depth of content combined with NewsGator's sophisticated RSS platform delivers a powerful Enterprise 2.0 solution."

Enterprise Alert Manager is available through subscription and can be purchased as a stand-alone service or in addition to a Dialog subscription. For more information about Enterprise Alert Manager, visit http://scientific.thomson.com/products/eam.

About The Thomson Corporation
The Thomson Corporation (www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at http://scientific.thomson.com.

Most Popular Now

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Moderna's COVID-19 vaccine candidate meets its pri…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Pfizer and BioNTech conclude Phase 3 study of COV…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based...

Pfizer and BioNTech to submit Emergency Use Author…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authori...

Phase 2 trial of Oxford COVID-19 vaccine in health…

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 ye...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Chinese vaccine candidate based on inactivated SAR…

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published in The Lanc...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...